Rule-based multi-scale simulation for drug effect pathway analysis

BMC Medical Informatics and Decision Making

Volumn 13, Issue SUPPL1, 2013, Pages

  Hwang, Woochang ^a   Hwang, Yongdeuk ^a   Lee, Sunjae ^a   Lee, Doheon ^a  

^a Korea Advanced Institute of Science and Technology (KAIST)   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

INSULIN;

ALGORITHM; ARTICLE; CLASSIFICATION; COMPUTER SIMULATION; DRUG COMBINATION; DRUG EFFECT; DRUG SURVEILLANCE PROGRAM; GENETICS; HUMAN; INSULIN RESISTANCE; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL; PHENOTYPE; PHYSIOLOGY; STANDARD;

ADVERSE DRUG REACTION REPORTING SYSTEMS; ALGORITHMS; COMPUTER SIMULATION; DIABETES MELLITUS, TYPE 2; DRUG COMBINATIONS; HUMANS; INSULIN; INSULIN RESISTANCE; INSULIN-SECRETING CELLS; PHENOTYPE;

MLCS; MLOWN;

EID: 84875921750     PISSN: None     EISSN: 14726947     Source Type: Journal    
DOI: 10.1186/1472-6947-13-S1-S4     Document Type: Article

References (28)

1. Systems pharmacology: network analysis to identify multiscale mechanisms of drug action. Zhao S, Iyengar R, Annual review of pharmacology and toxicology 2012 52 505 521 10.1146/annurev-pharmtox-010611-134520 22235860
2. Systems biology in drug discovery. Butcher EC, Berg EL, Kunkel EJ, Nature biotechnology 2004 22 10 1253 1259 10.1038/nbt1017 15470465
3. Novel computational approaches to polypharmacology as a means to define responses to individual drugs. Xie L, Kinnings SL, Bourne PE, Annual review of pharmacology and toxicology 2012 52 361 379 10.1146/annurev-pharmtox-010611- 134630 22017683
4. Drug discovery using chemical systems biology: identification of the protein-ligand binding network to explain the side effects of CETP inhibitors. Xie L, Li J, Bourne PE, PLoS computational biology 2009 5 5 1000387 10.1371/journal.pcbi.1000387 19436720
5. The anti-cancer drug lenalidomide inhibits angiogenesis and metastasis via multiple inhibitory effects on endothelial cell function in normoxic and hypoxic conditions. Lu L, Payvandi F, Wu L, Zhang LH, Hariri RJ, Man HW, Chen RS, Muller GW, Hughes CC, Stirling DI, et al. Microvascular research 2009 77 2 78 86 10.1016/j.mvr.2008.08.003 18805433
6. Network pharmacology. Hopkins AL, Nature biotechnology 2007 25 10 1110 1111 10.1038/nbt1007-1110 17921993
7. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. Baselga J, Cortes J, Kim SB, Im SA, Hegg R, Im YH, Roman L, Pedrini JL, Pienkowski T, Knott A, et al. The New England journal of medicine 2012 366 2 109 119 10.1056/NEJMoa1113216 22149875
8. The NCI60 human tumour cell line anticancer drug screen. Shoemaker RH, Nature reviews Cancer 2006 6 10 813 823 10.1038/nrc1951 16990858
9. Optimal drug combinations and minimal hitting sets. Vazquez A, BMC systems biology 2009 3 81 10.1186/1752-0509-3-81 19660129
10. Simulating quantitative cellular responses using asynchronous threshold Boolean network ensembles. Jack J, Wambaugh JF, Shah I, BMC systems biology 2011 5 109 10.1186/1752-0509-5-109 21745399
11. An enhanced Petri-net model to predict synergistic effects of pairwise drug combinations from gene microarray data. Jin G, Zhao H, Zhou X, Wong ST, Bioinformatics 2011 27 13 310 316 10.1093/bioinformatics/btr202 21685086
12. Models from experiments: combinatorial drug perturbations of cancer cells. Nelander S, Wang W, Nilsson B, She QB, Pratilas C, Rosen N, Gennemark P, Sander C, Molecular systems biology 2008 4 216 18766176
13. Genomics, type 2 diabetes, and obesity. McCarthy MI, The New England journal of medicine 2010 363 24 2339 2350 10.1056/NEJMra0906948 21142536
14. D N, The Music of Life: Biology Beyond the Genome Oxford University Press 2006
15. DT C, 'Downward causation' in hierarchically organised biological systems Macmillan Press 1974 1974 179 186
16. Danos V, Feret J, Fontana W, Harmer R, Krivine J, Rule-Based Modelling of Cellular Signalling CONCUR 2007-Concurrency Theory Springer Berlin/Heidelberg, Caires L, Vasconcelos V, 2007 4703 17 41 10.1007/978-3-540-74407-8-3
17. Rule-based modeling of biochemical networks. Faeder JR, Blinov ML, Goldstein B, Hlavacek WS, Complexity 2005 10 4 22 41 10.1002/cplx.20074
18. Rule-based whole body modeling for analyzing multi-compound effects. Hwang W, Hwang Y, Lee S, Lee D, Proceedings of the ACM Sixth International Workshop on Data and Text Mining in Biomedical Informatics New York: ACM 2012 77 84 10.1145/2390068.2390083
19. Finkel R, Pharmacology 2009
20. Anti-diabetic drugs inhibit obesity-linked phosphorylation of PPARgamma by Cdk5. Choi JH, Banks AS, Estall JL, Kajimura S, Bostrom P, Laznik D, Ruas JL, Chalmers MJ, Kamenecka TM, Bluher M, et al. Nature 2010 466 7305 451 456 10.1038/nature09291 20651683
21. Mechanisms linking obesity to insulin resistance and type 2 diabetes. Kahn SE, Hull RL, Utzschneider KM, Nature 2006 444 7121 840 846 10.1038/nature05482 17167471
22. Mechanisms of disease: molecular and metabolic mechanisms of insulin resistance and beta-cell failure in type 2 diabetes. Muoio DM, Newgard CB, Nature reviews Molecular cell biology 2008 9 3 193 205 10.1038/nrm2327 18200017
23. Cellular and molecular mechanisms of metformin: an overview. Viollet B, Guigas B, Sanz Garcia N, Leclerc J, Foretz M, Andreelli F, Clin Sci (Lond) 2012 122 6 253 270 10.1042/CS20110386 22117616
24. Discovering context-specific relationships from biological literature by using multi-level context terms. Lee S, Choi J, Park K, Song M, Lee D, BMC Medical Informatics and Decision Making 2012 12 Suppl 1 1 10.1186/1472-6947-12- S1-S1 22595086
25. Spatial modeling in cell biology at multiple levels. Bittig AT, Uhrmacher AM, Simulation Conference (WSC), Proceedings of the 2010 Winter: 5-8 Dec. 2010 2010 2010 608 619
26. The synergistic effect of miglitol plus metformin combination therapy in the treatment of type 2 diabetes. Chiasson JL, Naditch L, Diabetes care 2001 24 6 989 994 10.2337/diacare.24.6.989 11375358
27. Safety and efficacy of nateglinide/metformin combination therapy in the treatment of type 2 diabetes. Israel MK, Istvan E, Baron MA, Vascular health and risk management 2008 4 6 1167 1178 19337530
28. Effects of pioglitazone in combination with metformin or a sulfonylurea compared to a fixed-dose combination of metformin and glibenclamide in patients with type 2 diabetes. Comaschi M, Demicheli A, Di Pietro C, Bellatreccia A, Mariz S, Diabetes technology & therapeutics 2007 9 4 387 398 10.1089/dia.2006.0023 17705695